Hey readers! Here's something that would have sounded reckless a decade ago: some adults may now get a firm celiac diagnosis without ever having a scope put down their throat. The British Society of Gastroenterology just updated how adult celiac disease is diagnosed and followed, and there's a lot in this issue worth unpacking, from the new "no-biopsy" pathway to two drug pipelines quietly betting big on celiac.
🇬🇧 The main event: BSG's 2026 adult celiac guidelines
The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease lay out updated, evidence-based standards for diagnosing and managing adult celiac disease. The guideline was built by a multidisciplinary panel with contributors from the UK, Sweden, Italy, and Australia, prompted by recent advances in both diagnosis and treatment. – 2 Medical News
The headline change, and the one your patients will ask about, is the biopsy question. Per the Gluten-Free Brief, the new guidance allows adults with antibody levels above 10x the normal limit, confirmed with a second blood test, to skip the biopsy. That pathway is estimated to cover roughly 20 to 30% of symptomatic adults, still requires specialist confirmation, and carries one non-negotiable caveat: patients should keep eating gluten until testing is complete. – Gluten-Free Food Program
This mirrors a shift already established in pediatric practice, so it's less of a surprise than a catching-up. For clinicians, it means faster answers for a meaningful slice of patients and fewer scopes. For patients, the message worth repeating loudly is the one about not going gluten-free before testing. Cut gluten early and you can turn a clear-cut diagnosis into a frustrating gray zone.
Only 3 in 10 people felt informed at diagnosis.
That line from the same brief, drawn from a Celiac Disease Foundation registry analysis where only 29.8% of patients strongly agreed their doctor clearly explained disease management at diagnosis, is a useful reality-check against the tech of it all. A faster diagnostic pathway means little if the conversation at diagnosis still leaves most people confused. The BSG's emphasis on management and follow-up, not just the diagnostic label, is the part that should stick.
🔍 Why diagnosis matters so much: one family's story
York mum says doctors mistook coeliac disease for C-section complications tells the story of Sophie Fisher, 43, whose severe pain was attributed to scar tissue for years after she gave birth to twin sons in 2016, before a positive blood test and confirming endoscopy led to a celiac diagnosis in 2021. – BBC News
For years, being dismissed had made me feel like I was going mad.
Her experience is exactly the case the new antibody-first pathway aims to shorten. Guts UK estimates about one in 100 people in the UK have celiac disease, with roughly 70% still undiagnosed, and says her story shows how other serious digestive conditions can mask the signs. Fisher switched to a gluten-free diet and reports symptom improvement, but five years is a long time to spend feeling unheard.
💊 Two big pharma bets land on celiac
Here's a shift worth flagging for anyone following celiac treatment: two major deals this month put celiac disease at the center of the strategy, not the sidelines.
Sanofi's $1.4B Kymab bet falters again as atopic dermatitis trials scrapped reports that Sanofi is discontinuing most atopic dermatitis development for amlitelimab after its Phase 3 COAST-1 results did not show "meaningful improvement" over standard of care. – BioSpace
"Sanofi has determined that the totality of efficacy and safety evidence generated to date does not support further development of amlitelimab in AD,"
The celiac angle is what survives. Per BioSpace, Sanofi is still running a mid-stage amlitelimab trial in celiac disease with a readout expected in the second half of 2026. AktienSensor frames the pullback as freeing R&D resources toward higher-potential programs, celiac among them, and Sanofi says its full-year 2026 guidance is unchanged. – AktienSensor
The bigger move came this week. argenx to Acquire Forte Biosciences for $2.2 Billion reports a deal at $77 per share, described as an 86% premium over an 18-day trading window, tied to Phase 1b data for the anti-CD122 antibody FB102 showing statistically significant benefit in two autoimmune indications: vitiligo and celiac disease. – Clinical Trial Vanguard
FB102's Phase 1b celiac data from last year was strong enough that argenx is now waiting on Phase 2 results expected in the second half of 2026, results it will own entirely when the deal closes in Q3.
Two separate companies pointing to second-half-2026 celiac readouts is a genuine signal that celiac drug development is heating up. None of this replaces the gluten-free diet today, but it's a reminder that "diet is the only option" may not be a permanent statement.
🧬 What the science is teaching us
A few studies this month sharpen how we think about why celiac behaves the way it does.
New Study Finds Hidden Immune Cell Differences in Celiac Disease found that helper immune cells from people with celiac disease showed weaker expansion after activation, with evidence pointing to earlier cell death and less of a survival-supporting immune signal, and these differences appeared in both newly diagnosed patients and those already on a gluten-free diet. – Celiac.com
A new study examined whether people with celiac disease have built-in immune system differences that exist even before their immune cells are exposed to gluten.
That these patterns persist beyond active gluten exposure hints at a more stable immune programming, which could eventually inform immune-regulation therapies like the ones above.
For celiac disease patients, these gut bacterial enzymes could be good news describes two gut bacterial enzymes, PSP692 and PSP464, that degrade immunogenic gliadin peptides; in a Caco-2 cell model, predigesting gliadin fragments with them lowered IL-6 and restored barrier markers zonulin and occludin. – Nature
Celiac Disease and Gut Bacteria: Why High-Fibre Diets May Not Always Work reports a McMaster University study linking celiac disease to an absence of the bacterial family Prevotellaceae in the small intestine, and finding that inulin accelerated healing of gluten-induced injuries while the corn-based resistant starch Hylon VII did not. – Project PARC
The study's results indicate that supporting gut health in celiac disease might require a synbiotic approach - a combination of the right fiber and the right bacteria in the small intestine.
The practical takeaway: "eat more fiber" is too blunt. Fiber type and your resident microbes both matter, so blanket supplement advice may miss the mark for some patients.
👧 The pieces beyond the gut
Two studies remind us that celiac's toll isn't only physical, especially in younger patients.
Does Quality of Life and Symptom Severity Correlate with Celiac Disease Serology in Adolescents? found that among 54 adolescents with newly diagnosed symptomatic celiac disease, abnormal tTG-IgA was linked to lower overall quality-of-life scores and worse social, emotional, and school functioning, yet showed no significant relationship to physical symptoms. – Digestive Diseases and Sciences
Bullying victimization in pediatric patients with celiac disease compared 124 children with celiac disease to 139 controls and found significantly higher rates of peer bullying, with depressive symptoms, not bullying itself, remaining the independent predictor of dietary non-adherence. – Psychiatry AI
We therefore recommend that depressive symptom screening and treatment should be integrated into the management of celiac disease in children, particularly for those experiencing peer victimization.
Both point the same direction: for kids and teens, emotional and social wellbeing may be a bigger driver of both quality of life and diet adherence than symptoms alone. That's a strong argument for building mental health screening into follow-up, which fits neatly with the BSG guideline's focus on management, not just the diagnostic moment.
🏷️ Labels, beer, and screening in brief
AOECS welcomes landmark Codex agreement on gluten labelling: Codex adopted a science-based 4 mg gluten reference dose to standardize when "may contain" warnings are warranted, leaving the 20 ppm gluten-free threshold unchanged, with a key rule that a product needing a precautionary statement should not also carry a gluten-free claim. – AOECS
Study Looks at Gluten Residues in Gluten-Free Barley Beers: mass spectrometry detected 44 celiac-active protein fragments across barley-based beers, including seven gluten-free-labeled ones, though concentrations were very low and below the EU limit and the study does not show they cause harm. – Celiac.com
Why Children With Type 1 Diabetes Should Be Screened for Celiac Disease: in a Saudi retrospective study, 13.7% of screened children and adolescents with type 1 diabetes had positive celiac screening results, reinforcing the case for routine screening in this group. – Celiac.com
🍽️ A note on living gluten-free
Guidelines and drug trials are the long game. In the meantime, finding safe places to eat, at home or traveling, is the daily work. We're not sponsored by them, but Find Me Gluten Free remains one of the more practical tools out there for tracking down celiac-friendly restaurants and reading through real community reviews before you commit.
That's the issue. If the BSG changes prompt a conversation with your care team, remember the golden rule worth its own line: keep eating gluten until testing is done. Take care of yourselves.